Israel began a third dose of Pfizer’s mRNA Covid vaccine on July 30, amid a recent surge due to the delta mutation.
It was first approved by people over the age of 60 who received a second vaccination at least 5 months ago.
A study published in the New England Journal of Medicine showed a significantly lower incidence of confirmed Covid-19 and serious illness among those who received a third boost to the BNT162b2 vaccine. it was done.
In this study, the team extracted data from the Israeli Ministry of Health database from July 30 to August 31 for 1,137,804 people who were fully vaccinated (ie, twice vaccinated with BNT162b2) over the age of 60. Did. At least 5 months ago.
At least 12 days after booster administration, those who received booster had an 11-fold lower infection rate and a nearly 20-fold lower incidence of serious illness compared to those who received only two doses. Shown in.
This study is the latest addition to the discussion of the need for boosters.
US federal health officials, including top infectious disease expert Dr. Anthony S. Fauci, have justified plans to distribute booster shots, but many have opposed it.
In a recent review published at The Lancet, an international group of scientists, including scientists from the World Health Organization and the U.S. Food and Drug Administration, found that the effectiveness of the vaccine against severe Covid was very high, even in delta variants. At this stage of the pandemic, the general public is “not appropriate” because it is expensive.
Regulators said the US-approved vaccine now provides adequate protection against serious illness and death from Covid-19, without additional administration, the Wall Street Journal reported.
Even when the Biden administration is discussing the need for a third shot against Covid, the FDA’s stance on booster doses is coming.
Research, Health News, ET HealthWorld
Source link Research, Health News, ET HealthWorld